Related Experiment Videos
[Dibekacin in bronchopulmonary infectious pathology]
La Nouvelle Presse Medicale
|November 18, 1982
Summary
Intraparenteral dibekacin effectively treated bacterial bronchopulmonary infections in intensive care unit patients, showing good clinical outcomes and tolerance. The study found no evidence of cochlear or vestibular toxicity during treatment.
Area of Science:
- Infectious Diseases
- Pharmacology
- Critical Care Medicine
Context:
- Bacterial bronchopulmonary infections pose a significant threat to intensive care unit (ICU) patients.
- Antibiotic resistance necessitates the evaluation of novel therapeutic agents.
- Intraparenteral administration offers a direct route for drug delivery in severe infections.
Purpose:
- To evaluate the efficacy and safety of intraparenteral dibekacin in treating bacterial bronchopulmonary infections in ICU patients.
- To assess the clinical and biological response to dibekacin therapy.
- To monitor for any adverse effects, particularly cochlear and vestibular toxicity.
Summary:
- Thirty-six ICU patients with bacterial bronchopulmonary infections received intraparenteral dibekacin (3 mg/kg/day) for a mean of 14 days.
- Identified pathogens included staphylococci and Gram-negative bacilli, all sensitive to dibekacin.
- Favorable outcomes were observed in 26 patients, with clinical improvement in 10 others. Tolerance was good, with no reported cochlear or vestibular toxicity.
Impact:
- Intraparenteral dibekacin demonstrates potential as an effective treatment for severe bacterial bronchopulmonary infections in critically ill patients.
- The favorable safety profile, especially the absence of ototoxicity, is a significant finding for this antibiotic class.
- This study contributes to the evidence base for managing challenging respiratory tract infections in the ICU setting.